Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
- Independent arbitrator finds in favor of Alector in confidential arbitration proceedings
- Dr. Abeliovich remains bound by contractual obligations related to the confidentiality of the company’s intellectual property rights
“Alector is pleased with the arbitrator’s decision, confirming Dr. Abeliovich’s contractual obligations to Alector, and we look forward to bringing this legal matter to a conclusion,” said
Details relating to the arbitration proceeding and its outcome are confidential.
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to the Company’s plans for and anticipated benefits and mechanism of the Company’s product candidates, as set forth in Alector’s Quarterly Report on Form 10-Q filed with the
Vice President, Communications and Public Affairs
Source: Alector, Inc.